Last updated on July 2019

ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer


Brief description of study

A phase 1/2 multi-center investigation of ABI-009 (nab-rapamycin) in combination with mFOLFOX6 and Bevacizumab as first-line therapy in patients with advanced or metastatic colorectal cancer

Clinical Study Identifier: NCT03439462

Find a site near you

Start Over

HonorHealth Research Institute

Scottsdale, AZ United States
9.99miles
  Connect »